Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50090-6894

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 50090-6894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 01)

Chemical structure diagram of desvenlafaxine succinate, the active ingredient in the product Desvenlafaxine Succinate 50 mg extended-release tablets by A-S Medication Solutions.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 02)

A chart titled 'Figure 1 Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics,' displaying geometric mean ratios with 90% confidence intervals for Cmax and AUC values. The chart compares pharmacokinetic changes relative to reference across various renal impairment levels, hepatic impairment severities, and population subgroups by gender and age for Desvenlafaxine.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 03)

A figure titled 'Effect of Other Drugs on Desvenlafaxine Pharmacokinetics' showing the impact of CYP3A4 inhibitor Ketoconazole on pharmacokinetic parameters Cmax and AUC. The chart presents geometric mean ratios with 90% confidence intervals relative to reference values, indicating a slight increase in Cmax and a more pronounced increase in AUC.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 04)

A bar graph displaying the effects of Desvenlafaxine on the pharmacokinetics of other drugs, showing geometric mean ratios with 90% confidence intervals for Cmax and AUC values of Desipramine, Midazolam, Tamoxifen, and Aripiprazole at different Desvenlafaxine doses.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 05)

A line graph compares the estimated proportion of patients experiencing relapse over time (days since randomization) between two groups: those taking Desvenlafaxine extended-release tablets 50 mg and those taking a placebo. The x-axis represents time to relapse in days, and the y-axis shows the estimated proportion of patients with relapse in percentage. The graph shows lower relapse rates for the Desvenlafaxine group compared to placebo throughout the study period.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 06)

A line graph comparing the estimated proportion of patients with relapse over time in days for Desvenlafaxine extended-release tablets versus placebo. The x-axis represents time to relapse in days from randomization, and the y-axis shows the estimated proportion of patients with relapse as a percentage. Two lines depict relapse rates, with the placebo group having a higher relapse proportion over time than the Desvenlafaxine group.*

FDA Label Image

Label Image (Lbl500906894)

Desvenlafaxine Succinate 50 mg extended-release film-coated tablets label from A-S Medication Solutions. The label states each tablet contains 76 mg of Desvenlafaxine Succinate equivalent to 50 mg of the monohydrate, in a unit of use package with 30 tablets. Storage instructions indicate keeping at 20 to 25 degrees Celsius (controlled room temperature). The label includes the NDC 50090-6894-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.